Become A Featured Company

MediPharm Labs Inc.: Built for Purity in Cannabis Extraction

Ryan Allway

August 31st, 2018

Exclusive, News, Top Story

Cannabis oils and extracts have quickly become the fastest growing segment of the global cannabis industry. In the United States, cannabis concentrate sales rose more than 50 percent last year, compared to a decline in cannabis flower sales across most markets. In Canada, cannabis extracts have already become more popular than cannabis flower for medical patients — a trend that could accelerate with the legalization of recreational cannabis in October.

MediPharm Labs Inc. has focused exclusively on becoming a leader in cannabis extraction with the most sophisticated and largest extraction footprint in the country. Investors looking for a pure play opportunity in cannabis extraction may want to take a closer look at the company as it prepares to go public soon.

Click here to get a MediPharm going public alert and corporate presentation.

From Flower to Extracts

Health Canada has reported a consistent increase in cannabis oil and extract sales. Between April and December of last year, cannabis flower sales rose 9.2 percent to 2,079 kilograms compared to a 56.7 percent increase in cannabis oil sales to 3,005 kilograms. Inventories of cannabis oil are also much tighter at just 11,140 kilograms compared to 38,927 kilograms for cannabis flower, suggesting that prices could continue to rise.

There are several reasons for these trends:

  • Higher Margins – Cannabis extracts create higher margin products than cannabis flower, ranging from recreational edibles to pharmaceutical-grade medical products.
  • Longer Shelf Life – Cannabis extracts have a longer shelf life than cannabis flower, which makes them preferable from an inventory standpoint.
  • Physician Supported – Many physicians prefer extracts because of the improved safety (no smoke inhalation) and efficacy (more predictable effects with exact dosing).

The Opportunity: Many licensed producers are not very well equipped to produce cannabis oil since they have focused largely on cultivating cannabis flower. While some companies are providing in-house extraction technology to a number of producers, many licensed producers are opting to partner with a third party that is already an expert at extraction. That way, each company can focus on what it does best and maximize its efficiency and returns. 

MediPharm’s Purity Focus

MediPharm was the first company in Canada to secure Licensed Producer approval for oils from Health Canada without first receiving a cannabis cultivation license. MediPharm is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. With the current ability to process over 100,000 kilograms of dried cannabis per year (and expansion plans to go to 300,000 kilograms of dried cannabis per year in its Barrie Ontario operations), the company has the largest cannabis oil production footprint in the country. MediPharm plans to partner with Licensed Producers and other parties to bring both medical and recreational advanced derivative products to market. The company’s extraction methodology results in exceptional purity, offering trust and assurance to end consumers.

Click here to get a MediPharm going public alert and corporate presentation.

Within a month of being licensed, the company secured over 1,000 kilograms in dried cannabis supply contracts and its professional business development team is driving future supply with fixed volume contracts, product-focused partnerships with licensed producers, and one-off bulk purchases. The company is working with licensed producers to manufacture and distribute pharma-grade extract-based products under joint ventures, white-label partnerships, and other agreements.

Management is also focused on building an international presence through its MediPharm Labs Australia Pty. Ltd. subsidiary. The facility will act as an important import hub until Australian domestic patient demand warrants dedicated production activity. With the Australian government’s recent move to legalize medical cannabis exports, the country could become one of the largest players in the global cannabis industry.

The company’s management team is also well-equipped to build long-term shareholder value:

  • Pat McCutcheon – President and CEO – Pharmaceutical sales and marketing expert.
  • Keith Strachan – Business Development – Healthcare business development expert.
  • Ahmed Shehata – General Counsel – Corporate and commercial law expert.
  • Martha Smart – Director of Innovation – Pharmaceutical product experience.
  • Chris Hobbs – Chief Financial Officer – CPA with finance and compliance experience.
  • Chris Talpas – Director of QA – Biomanufacturing and cGMP operations expert.
  • Paul Hamelin – Director of Security – Public safety and risk management expert.
  • Sybil Taylor – Chief Marketing Officer – CPG and strategic marketing expert.

Looking Ahead

MediPharm represents a compelling investment opportunity in Canada’s cannabis industry. With the largest extraction operation in the country and a focus on international quality standards, the company is well positioned to partner with leading licensed producers and fulfill a key gap in the industry. Investors looking for a pure-play opportunity in the extracts space may want to take a closer look at the company as it gears up to go public over the near-term.

Click here to get a MediPharm going public alert and corporate presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading